Guggenheim initiated coverage of Olema Oncology (OLMA) with a Buy rating and $20 price target The firm sees the company emerging as the best positioned biotech for the selective estrogen receptor degraders breast cancer drug class. Olema’s palazestrant has the “most interesting” monotherapy and CDK combination data of all competitors, the analyst tells investors in a research note. It believes the drug is well positioned in a $10B market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Promising Potential of Olema Pharmaceuticals’ Palazestrant in ESR1 Patient Treatment Drives Buy Rating
- Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA
- Olema Pharmaceuticals: Strategic Positioning and Promising Outlook in the Oral SERD Market
- Oppenheimer says Olema collaboration with Pfizer could lead to bidding war
- Buy Recommendation for Olema Pharmaceuticals Driven by Strategic Collaborations and Promising Clinical Developments